...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: a $6 sell order drops ZEN 96% !

Hey Fuzzy ,

I will hold to that , waiting for bated breath when Zenith come through via a buyout ,I think if the prostate trial passes the next phase it's as good as sold , could be a royalty or partnership deal prior to that however 

 

Share
New Message
Please login to post a reply